DNA2 inhibitors for cancer treatment
Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
1. A method of treating cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of a tautomer thereof; wherein the cancer is breast cancer, colon cancer, prostate cancer, lung cancer, or ovarian cancer; and wherein the compound is:
2. The method of claim 1 , further comprising administering to the patient a chemotherapeutic agent.
3. The method of claim 2 , wherein the chemotherapeutic agent is a PARP inhibitor.
4. The method of claim 2 , wherein the chemotherapeutic agent is a topoisomerase inhibitor.
5. The method of claim 4 , wherein the topoisomerase inhibitor is a topoisomerase I inhibitor.
6. The method of claim 2 , wherein the chemotherapeutic agent is irinotecan, topotecan, camptothecin, lamellarin D, etoposide, teniposide, doxorubicin, daunorubicin, mitoxantrone, amsacrine, ellipticines, aurintricarboxylic acid, HU-331, epigallocatechin gallate, genistein, quercetin, resveratrol, or a combination of two or more thereof.
7. The method of claim 1 , further comprising administering radiation to the patient.
8. The method of claim 2 , further comprising administering radiation to the patient.